Literature DB >> 24958503

Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel.

Dahlia Weitzman1, Gabriel Chodick1, Varda Shalev1, Chagai Grossman1, Ehud Grossman2.   

Abstract

Previous assessments of the prevalence of resistant hypertension (RH) in uncontrolled blood pressure (BP) have ranged from 3% to 30%. Using real-world data, our aim was to estimate the prevalence of RH in patients belonging to the Maccabi Healthcare Services, a 2-million-member health organization in Israel. From 2010 to 2011, all hypertensive patients with ≥2 recorded BP measurements during a minimum period of 6 months were identified. Patients were considered uncontrolled if their most recent BP during the study period and their mean systolic BP or diastolic BP during a preceding period of ≥6months were systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, or systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg in chronic kidney disease or diabetes mellitus. Uncontrolled patients taking diuretics and ≥2 antihypertensive therapy classes at their maximal recommended dose were regarded as resistant hypertensives. A total of 172 432 patients were eligible for the study. Uncontrolled BP was found in 35.9% (n=65 710). Overall, 2.2% of the uncontrolled patients (n=1487) were resistant hypertensives. Patients with RH were characterized by a significantly (P<0.01) older age, higher body mass index, and multicomorbidity (including dyslipidemia, diabetes mellitus, and impaired renal function) compared with patients with controlled hypertension receiving equivalent treatment. The results of this large population-based study indicate a substantially lower prevalence of RH than previously reported. Most patients with uncontrolled BP took less than the maximal recommended antihypertensive treatment.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  diagnosis; epidemiology; hypertension; obesity; pharmaceutical preparations

Mesh:

Substances:

Year:  2014        PMID: 24958503     DOI: 10.1161/HYPERTENSIONAHA.114.03718

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  39 in total

Review 1.  Carotid baroreflex activation therapy for resistant hypertension.

Authors:  Ronald G Victor
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

2.  Controlling Hypertension: We Have the Tools-We Just Need to Use Them.

Authors:  David J Hyman; Valory Pavlik
Journal:  J Gen Intern Med       Date:  2017-08       Impact factor: 5.128

Review 3.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

Review 4.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 5.  Recognition and Management of Resistant Hypertension.

Authors:  Branko Braam; Sandra J Taler; Mahboob Rahman; Jennifer A Fillaus; Barbara A Greco; John P Forman; Efrain Reisin; Debbie L Cohen; Mohammad G Saklayen; S Susan Hedayati
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-28       Impact factor: 8.237

6.  Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension.

Authors:  Andrew Y Hwang; Chintan V Dave; Steven M Smith
Journal:  Am J Hypertens       Date:  2018-11-13       Impact factor: 2.689

7.  Implications of Guideline Updates for the Management of Apparent Treatment Resistant Hypertension in the United States (A NCDR Research to Practice [R2P] Project).

Authors:  Anna M Maw; Lauren E Thompson; P Michael Ho; Kevin F Kennedy; Thomas M Maddox; Javier A Valle; Amneet Sandhu; Frederick A Masoudi; Franz H Messerli; Stacie L Daugherty
Journal:  Am J Cardiol       Date:  2019-10-11       Impact factor: 2.778

Review 8.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

9.  Incidence, aetiology and mortality secondary to hypertensive emergencies in a large-scale referral centre in Israel (1991-2010).

Authors:  A Leiba; O Cohen-Arazi; L Mendel; E J Holtzman; E Grossman
Journal:  J Hum Hypertens       Date:  2015-12-17       Impact factor: 3.012

10.  Refractory versus resistant hypertension: Novel distinctive phenotypes.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Nitin Gharpure; David A Calhoun
Journal:  J Nat Sci       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.